ID: ALA1277623

Max Phase: Preclinical

Molecular Formula: C26H32N4O6S2

Molecular Weight: 560.70

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  N[C@H]1CCSSC[C@@H](C(=O)NCc2ccccc2CC(=O)O)NC(=O)C[C@H](Cc2ccc(O)cc2)NC1=O

Standard InChI:  InChI=1S/C26H32N4O6S2/c27-21-9-10-37-38-15-22(26(36)28-14-18-4-2-1-3-17(18)12-24(33)34)30-23(32)13-19(29-25(21)35)11-16-5-7-20(31)8-6-16/h1-8,19,21-22,31H,9-15,27H2,(H,28,36)(H,29,35)(H,30,32)(H,33,34)/t19-,21-,22-/m0/s1

Standard InChI Key:  VZYRMNZEFCZSER-BVSLBCMMSA-N

Associated Targets(Human)

Cystinyl aminopeptidase 313 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Aminopeptidase N 863 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Interleukin-1 receptor antagonist protein 102 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Endoplasmic reticulum aminopeptidase 2 387 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Endoplasmic reticulum aminopeptidase 1 581 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 560.70Molecular Weight (Monoisotopic): 560.1763AlogP: 1.35#Rotatable Bonds: 7
Polar Surface Area: 170.85Molecular Species: ACIDHBA: 8HBD: 6
#RO5 Violations: 2HBA (Lipinski): 10HBD (Lipinski): 7#RO5 Violations (Lipinski): 2
CX Acidic pKa: 4.18CX Basic pKa: 8.38CX LogP: -1.63CX LogD: -1.66
Aromatic Rings: 2Heavy Atoms: 38QED Weighted: 0.27Np Likeness Score: 0.57

References

1. Andersson H, Demaegdt H, Vauquelin G, Lindeberg G, Karlén A, Hallberg M, Erdélyi M, Hallberg A..  (2010)  Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP).,  53  (22): [PMID:21047126] [10.1021/jm100793t]
2. Mpakali A, Saridakis E, Giastas P, Maben Z, Stern LJ, Larhed M, Hallberg M, Stratikos E..  (2020)  Structural Basis of Inhibition of Insulin-Regulated Aminopeptidase by a Macrocyclic Peptidic Inhibitor.,  11  (7): [PMID:32676150] [10.1021/acsmedchemlett.0c00172]
3. Barlow, Nicholas, Vanga, Sudarsana Reddy, Savmarker, Jonas, Sandstrom, Anja, Burns, Peta, Hallberg, Anders, Aqvist, Johan, Gutierrez-de-Teran, Hugo, Hallberg, Mathias, Larhed, Mats, Chai, Siew Yeen, Thompson, Philip E..  (2020)  Macrocyclic peptidomimetics as inhibitors of insulin-regulated aminopeptidase (IRAP),  11  (2): [PMID:33479630] [10.1039/c9md00485h]

Source